Harrow Health stock falls 1.55 percent despite Q2 growth

Published on 09/24/2026 at 21:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harrow Health stock traded at USD 33.08 on September 24, 2026, below its USD 54.85 52-week high. Q2 revenue reached USD 70.66 million against USD 70.35 million consensus.

HROW, US4158581094, Illustration mit AI erstellt.

Harrow Health stock (ISIN US4158581094) was trading at USD 33.08 on Nasdaq on September 24, 2026, down 1.55 percent from the previous close. The decline came as investors weighed Q2 revenue growth against a wider earnings loss.

Revenue beat meets earnings pressure

Harrow reported Q2 2026 revenue of USD 70.66 million, compared with a USD 70.35 million consensus estimate. The result exceeded revenue expectations by USD 0.31 million, while adjusted earnings per share came in at a loss of USD 0.46, USD 0.28 below consensus, according to MarketBeat.

The latest quarter still showed operating scale. Q2 revenue rose 11 percent year over year to USD 70.7 million, while VEVYE revenue reached USD 29.4 million and IHEEZO revenue reached USD 15.6 million, per The Globe and Mail.

Guidance keeps the growth test high

Management reiterated full-year 2026 revenue guidance of USD 350 million to USD 365 million and adjusted EBITDA guidance of USD 80 million to USD 100 million. With first-half revenue at USD 115 million, the second half carries the larger execution burden.

That burden matters because Q2 GAAP gross margin was 71 percent, while adjusted EBITDA was negative USD 1.2 million. The combination gives the stock a clear operating test: product demand must convert into revenue growth and improving profitability.

Analyst view shifts to hold

MarketBeat reported that Zacks Research upgraded Harrow from strong sell to hold. The broader consensus remained Moderate Buy with a USD 66.38 price target, placing the published target USD 33.30 above the September 24 trading price.

Stock remains below yearly high

Harrow Health stock was trading at USD 33.08 on Nasdaq on September 24, 2026, with a 52-week range of USD 28.54 to USD 54.85. Its market capitalization was USD 1,233,060,540, making the earnings and guidance gap more important than the daily move alone.